Eton Pharmaceuticals (ETON) said Friday it completed the asset purchase deal to acquire Increlex from Ipsen.

Increlex, a biologic indicated for the treatment of patients 2 years to 18 years of age with severe primary insulin-like growth factor 1 deficiency, will now be available in the US exclusively through AnovoRx, according to the company.

Ipsen will continue to distribute Increlex outside the US for a six-month transition period and after that Eton will take over commercialization, Eton added.

Financial terms of the asset purchase agreement were not disclosed.

Shares of Eton were up 3.7% in recent trading.

Price: 12.73, Change: +0.45, Percent Change: +3.66